IRIS
CAVALLI, GIULIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.988
AS - Asia 2.515
NA - Nord America 1.956
SA - Sud America 664
AF - Africa 62
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 1
Totale 8.190
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.853
RU - Federazione Russa 1.743
SG - Singapore 898
CN - Cina 794
BR - Brasile 536
SE - Svezia 404
HK - Hong Kong 332
IT - Italia 258
VN - Vietnam 252
DE - Germania 158
FR - Francia 133
GB - Regno Unito 82
FI - Finlandia 66
AR - Argentina 61
CA - Canada 55
IN - India 45
BD - Bangladesh 38
MX - Messico 31
ZA - Sudafrica 28
EC - Ecuador 25
AT - Austria 24
PL - Polonia 24
TR - Turchia 22
IQ - Iraq 21
NL - Olanda 21
ID - Indonesia 20
IE - Irlanda 20
ES - Italia 18
JP - Giappone 17
PK - Pakistan 14
CO - Colombia 11
VE - Venezuela 11
MA - Marocco 9
KE - Kenya 8
PY - Paraguay 8
UA - Ucraina 8
UZ - Uzbekistan 8
PH - Filippine 7
CL - Cile 6
SA - Arabia Saudita 6
AZ - Azerbaigian 5
IR - Iran 5
NP - Nepal 5
PE - Perù 5
TN - Tunisia 5
BG - Bulgaria 4
EG - Egitto 4
AE - Emirati Arabi Uniti 3
IL - Israele 3
JO - Giordania 3
LT - Lituania 3
PA - Panama 3
TW - Taiwan 3
AL - Albania 2
AO - Angola 2
BE - Belgio 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
EU - Europa 2
GT - Guatemala 2
HN - Honduras 2
HR - Croazia 2
JM - Giamaica 2
NO - Norvegia 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SV - El Salvador 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
BH - Bahrain 1
BW - Botswana 1
CH - Svizzera 1
CU - Cuba 1
CY - Cipro 1
CZ - Repubblica Ceca 1
EE - Estonia 1
GA - Gabon 1
GR - Grecia 1
HT - Haiti 1
HU - Ungheria 1
KG - Kirghizistan 1
KH - Cambogia 1
KI - Kiribati 1
KR - Corea 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
ME - Montenegro 1
MN - Mongolia 1
MY - Malesia 1
NI - Nicaragua 1
OM - Oman 1
PS - Palestinian Territory 1
RS - Serbia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 8.190
Salva come PNG Salva come JPEG
Città #
Singapore 371
Moscow 355
Hong Kong 328
Dallas 289
Ashburn 265
San Jose 218
Shanghai 172
Hefei 119
Lawrence 107
Princeton 107
New York 105
Lauterbourg 103
Beijing 93
Ho Chi Minh City 92
Milan 69
Los Angeles 64
Munich 52
Hanoi 49
São Paulo 47
Boardman 42
Helsinki 32
Nuremberg 32
Turku 23
Denver 22
Rio de Janeiro 22
Atlanta 20
Montreal 20
Orem 20
Guangzhou 19
Chennai 18
Dublin 18
Poplar 18
Rome 18
Santa Clara 18
Cesano Boscone 17
Chicago 17
Johannesburg 17
London 17
Seattle 17
Warsaw 17
Tokyo 13
Brooklyn 12
Frankfurt am Main 12
Houston 12
Mexico City 12
Stockholm 12
Amsterdam 10
Brasília 10
Da Nang 10
Lappeenranta 10
Ankara 9
Council Bluffs 9
Hải Dương 9
Mumbai 9
Toronto 9
Belo Horizonte 8
Curitiba 8
Haiphong 8
Manchester 8
Pietra Ligure 8
The Dalles 8
Vienna 8
Guayaquil 7
Jakarta 7
Nairobi 7
Porto Alegre 7
Quito 7
Tashkent 7
Tianjin 7
Baghdad 6
Bologna 6
Buenos Aires 6
Can Tho 6
Falkenstein 6
Istanbul 6
Lahore 6
Pune 6
Querétaro 6
Salvador 6
Uberlândia 6
Xi'an 6
Baku 5
Bauru 5
Buffalo 5
Campinas 5
Cape Town 5
Jiaxing 5
Phoenix 5
Quezon City 5
Saint Louis 5
Thái Bình 5
Verona 5
Vitória 5
Wolfhagen 5
Biên Hòa 4
Boston 4
Brescia 4
Columbia 4
Corrientes 4
Fortaleza 4
Totale 3.873
Salva come PNG Salva come JPEG
Nome #
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 195
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 169
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 162
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study 141
Anakinra for patients with COVID-19: an updated systematic review and meta-analysis 131
Adherence to the Mediterranean Diet in Italian Patients With Systemic Sclerosis: An Epidemiologic Survey 126
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: An open-label cohort study 126
A bitter effect: thrombocytopenia induced by a quinidine-containing beverage 124
3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target 117
A Novel Histiocytosis With Synovial and Skin Involvement 115
Cardiovascular involvement in Erdheim-Chester diseases is associated with myocardial fibrosis and atrial dysfunction 115
Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease 110
Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series 106
Testosterone in males with COVID-19: A twelve-month cohort study 105
High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilation 104
Assessing the role of pentraxin-3 in Takayasu's arteritis. Comment on: Plasma pentraxin-3 levels in patients with Takayasu's arteritis during routine follow-up. Alibaz-Oner F. et al 103
Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis 101
Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production 100
Anakinra therapy for non-cancer inflammatory diseases 99
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation 99
Advances in potential targeted therapies for Erdheim-Chester disease 98
Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies 98
DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILL'S DISEASE IN THE PRE-CANAKINUMAB ERA 97
A virus-free cellular model recapitulates several features of severe COVID-19 97
Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience 96
Immunosuppressive strategies in invasively ventilated ARDS COVID-19 patients 95
Interleukin 1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study 92
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease 91
Autoimmune vitiligo is associated with gain-offunction by a transcriptional regulator that elevates expression of HLA-A∗02:01 in vivo 91
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study 91
Oncogene-induced senescence in hematopoietic progenitors features myeloid restricted hematopoiesis, chronic inflammation and histiocytosis 89
Autophagy and Protein Secretion 88
BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. 87
Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series 87
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis 87
An enlightening scan 86
Mechanisms of hematopoietic clonal dominance in VEXAS syndrome 85
Current treatment options and safety considerations when treating adult-onset Still’s disease 84
Aortic thrombosis secondary to clopidogrel-related thrombotic thrombocytopenic purpura 83
Anakinra for COVID-19: how to interpret elevations in serum liver enzymes 83
Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis 78
ROLE OF TRAINED IMMUNITY AND IMMUNOMETABOLISM IN THE PATHOGENESIS OF ERDHEIM-CHESTER DISEASE 73
Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease 73
Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout 72
Anakinra for patients with COVID-19 – Authors' reply 72
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial 71
Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes 70
Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli 70
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study 69
Interleukin-1 receptor blockade rescues myocarditis-associated end-stage heart failure 68
Cardiac magnetic resonance in systemic sclerosis patients with cardiac symptoms: do we really need it? 68
Testosterone in males with COVID-19: A 7-month cohort study 68
Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab 66
The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunity 65
Immunometabolic activation of macrophages leads to cytokine production in the pathogenesis of KRAS-mutated histiocytosis 65
Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition 64
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies 64
Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance: Report of Two Cases and Rationale for Its Therapeutic Use 64
QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic risk 63
Impact of rare and common genetic variation in the interleukin-1 pathway on human cytokine responses 61
Methotrexate in refractory bilateral juvenile temporal arteritis: Report of a case 59
Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset still's disease: A multicentre retrospective observational study 59
Myocarditis: An Interleukin-1-Mediated Disease? 58
Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement 58
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease 57
Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance 57
The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease 57
Relationship Between Ventricular Arrhythmias, Conduction Disorders, and Myocardial Fibrosis in Patients With Systemic Sclerosis: The Role of Cardiac Magnetic Resonance 57
Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients 56
Treating Pulmonary Silicosis by Blocking Interleukin 1 55
Diagnosing Erdheim-Chester disease 54
Gender differences in clinical presentation and vascular pattern in patients with Takayasu arteritis 54
Charcot's arthropathy of the spine 54
Large-scale use of hydroxychloroquine for COVID-19 confirms safety, if not effectiveness 54
Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: a single-center case series 53
Treating Experimental Arthritis with the Innate Immune Inhibitor IL-37 Reduces Joint and Systemic Inflammation 53
The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. 52
Priorities of biomedical research 52
Large Vessel Vasculitis Affecting the Aorta and Its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature 52
Efficacy and safety of biological agents in adult-onset Still's disease 51
TUMOUR NECROSIS FACTOR-ALPHA AS A MASTER REGULATOR OF INFLAMMATION IN ERDHEIM-CHESTER DISEASE: RATIONALE FOR THE SUCCESSFUL TREATMENT OF TWO PATIENTS WITH INFLIXIMAB 51
Tocilizumab in patients with multisystem Erdheim–Chester disease 51
Suppression of inflammation and acquired immunity by IL-37 51
Publications are not the finish line: Focusing on societal rather than publication impact 50
Prevalence of Takayasu arteritis in young women with acute ischemic heart disease 50
Letter by Campochiaro et al regarding article, “Clinical features, management, and outcomes of immune checkpoint inhibitor–Related cardiotoxicity” 49
Hypertrophic cardiomyopathy secondary to hepatitis C virus-related vasculitis 48
Treating Life-Threatening Myocarditis by Blocking Interleukin-1 48
MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo 47
CARDIAC CINE MRI IN ERDHEIM-CHESTER DISEASE: DATA FROM A LARGE ITALIAN COHORT 47
CLINICAL PRESENTATION OF ERDHEIM-CHESTER DISEASE: DATA FROM A COHORT 47
Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients 47
Erratum: Management of adult-onset Still's disease with interleukin-1 inhibitors: Evidence- And consensus-based statements by a panel of Italian experts (Arthritis Res Ther (2019) 21:275 DOI: 10.1186/s13075-019-2021-9) 46
Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease 46
Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease 45
Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response 45
Charcot's arthropathy of the hip 45
Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease 44
Orthopnea with platydeoxia secondary to prominent Eustachian valve 44
Cardiovascular disease in patients with rheumatoid arthritis: impact of classic and disease-specific risk factors 44
Totale 7.664
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.951
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.951
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20218 0 0 0 0 0 0 0 0 0 0 6 2
2021/2022128 1 0 32 31 11 11 4 2 21 3 8 4
2022/2023678 240 157 53 5 12 81 27 52 33 2 8 8
2023/2024496 17 40 60 43 48 72 23 52 5 8 40 88
2024/20251.782 179 31 37 51 67 122 197 221 346 232 134 165
2025/20265.207 345 390 410 786 388 152 395 401 1.509 320 111 0
Totale 8.424